Early tacrolimus exposure does not impact long-term outcomes after liver transplantation

Table 1 Donors and recipients characteristics

	≤ 10 ng/mL, n = 98	> 10 ng/mL, n = 57	P value
Donors
Age, year (mean ± SD)	54.7 ± 17.5	54.7 ± 17.5	0.002
Male	58 (59.2%)	35 (61.4%)	0.786
Cause of death			0.004
Stroke	57 (58.2%)	48 (84.2%)
Trauma	27 (27.6%)	6 (10.5%)
Other	14 (14.3%)	3 (5.3%)
Graft steatosis	19 (19.6%)	12 (21.1%)	0.827
Recipients
Age, years (mean ± SD)	55.3 ± 8.4	53.2 ± 9.8	0.227
Male	81 (82.7%)	48 (84.2%)	0.802
MELD (mean ± SD)	13.1 ± 5.6	12.7 ± 5.3	0.618
Hepatocellular carcinoma	45 (45.9%)	29 (50.9%)	0.551
Cause of liver disease			0.283
Alcohol abuse	45 (45.9%)	24 (42.1%)
HCV	40 (40.8%)	18 (31.6%)
HBV	3 (3.1%)	5 (8.8%)
Cho/estatic liver disease	3 (3.1%)	4 (7%)
Other	7 (7.1%)	6 (10.5%)
Medical history (pre LT)
MDRD-4 (mean ± SD)	107.8 ± 35.7	16.7 ± 33.7	0.223
Diabetes mellitus	18 (18.4%)	9 (15.8%)	0.683
Arterial hypertension	12 (12.2%)	10 (17.5%)	0.362
Mean tacrolimus trough levels 1 mo (ng/mL)	7.38 ± 1.68	12.62 ± 2.25	NA
Corticosteroids	80 (82.5%)	49 (86.0%)	0.571
Mycophenolate mofetil	32 (32.7%)	9 (15.8%)	0.024

MELD: Model for end-stage liver disease; MDRD-4: Modification of diet in renal disease; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; LT: Liver transplantation.